Latest Period
Q2 2026
Security Snapshot
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) Institutional Ownership
CUSIP: 98420X202
13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026
Institutions Reporting
88
Shares (Excl. Options)
95,923,522
Price
$4.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- XFOR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 95,923,522
- Total 13F value
- $447,942,684
- Portfolio coverage rank
- 0.01%
- Share change
- +5,510,475
- Value change
- +$27,454,778
- Number of holders
- 88
- Shares outstanding
- 96,529,340
- SEC-reported price per share
- $4.00
- Insider filing price
- $4.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share is tracked under CUSIP 98420X202.
- 88 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 80 to 88 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $373,355,951 to $447,942,684.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 88 institutions filings for Q2 2026.
Security key
98420X202
Latest holder period
Q2 2026
13F holders
88
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
XFOR full holder history
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
X4 Pharmaceuticals, Inc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98420X202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
XFOR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP | 10% | 0% | $35,180,748 | +$25,462,897 | 9,043,894 | +262% | Empery Asset Management, LP | 31 Dec 2025 |
| MORGAN STANLEY | 10% | +8.9% | $29,940,219 | +$2,318,051 | 8,884,338 | +8.4% | Morgan Stanley | 28 Feb 2026 |
| FMR LLC | 9.7% | $33,996,400 | 8,499,100 | FMR LLC | 31 Oct 2025 | |||
| PERCEPTIVE ADVISORS LLC | 8.1% | +6.2% | $35,654,876 | +$8,909,638 | 8,085,006 | +33% | Perceptive Advisors LLC | 30 Jun 2026 |
| Deep Track Capital, LP | 8.3% | -17% | $35,460,343 | +$25,021,895 | 8,040,894 | +240% | Deep Track Capital, LP | 30 Jun 2026 |
| Saturn V Capital Management LP | 7.4% | $25,026,241 | 6,433,481 | Saturn V Capital Management LP | 24 Oct 2025 | |||
| BlackRock, Inc. | 5.9% | +97% | $25,823,106 | +$24,986,592 | 5,529,573 | +2987% | BlackRock, Inc. | 30 Jun 2026 |
| Trails Edge Capital Partners, LP | 5.8% | -41% | $20,333,894 | +$11,320,168 | 5,227,222 | +126% | Trails Edge Capital Partners, LP | 31 Dec 2025 |
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | -38% | $17,496,802 | +$9,734,867 | 5,057,610 | +125% | Growth Equity Opportunities 18 VGE, LLC | 27 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 3.9% | -60% | $13,272,653 | +$4,544,819 | 3,411,993 | +52% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Coastlands Capital LP | 10% | 0% | $7,773,911 | +$37,418 | 2,491,638 | +0.48% | Coastlands Capital LP | 03 Oct 2025 |
| Nantahala Capital Management, LLC | 2.8% | -72% | $9,528,431 | +$798,030 | 2,449,468 | +9.1% | Nantahala Capital Management, LLC | 31 Dec 2025 |
As of 30 Jun 2026, 88 institutional investors reported holding 95,923,522 shares of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR). This represents 99% of the company’s total 96,529,340 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
96%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 9.8% | 9,461,279 | -0.06% | 0% | $44,184,173 |
| FMR LLC | 8.6% | 8,321,657 | +2.7% | 0% | $38,862,138 |
| Bain Capital Life Sciences Investors, LLC | 8.3% | 7,967,454 | 0% | 2.2% | $37,208,011 |
| PERCEPTIVE ADVISORS LLC | 8.2% | 7,933,491 | +18% | 0.58% | $37,049,403 |
| Saturn V Capital Management LP | 7.2% | 6,973,343 | +8% | 4.7% | $32,565,512 |
| Empery Asset Management, LP | 7.2% | 6,930,591 | -23% | 37% | $32,365,860 |
| Deep Track Capital, LP | 6.1% | 5,878,757 | -7.3% | 0.4% | $27,453,795 |
| BlackRock, Inc. | 5.8% | 5,554,906 | +358% | 0% | $25,941,411 |
| Kalehua Capital Management LLC | 3.9% | 3,722,840 | 0% | 10% | $17,385,663 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 3,715,859 | +6.2% | 0% | $17,353,062 |
| Rosalind Advisors, Inc. | 3.3% | 3,214,766 | 0% | 5.6% | $15,012,957 |
| BRAIDWELL LP | 3% | 2,922,754 | -11% | 0.5% | $13,649,261 |
| Blackstone Inc. | 2.8% | 2,681,922 | 0% | 0.04% | $12,524,576 |
| Trails Edge Capital Partners, LP | 2.7% | 2,571,478 | 0% | 1.9% | $12,008,803 |
| Nantahala Capital Management, LLC | 2.5% | 2,449,468 | 0% | 0.69% | $11,439,016 |
| BVF INC/IL | 2.3% | 2,233,742 | 0% | 0.27% | $10,431,575 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 2,098,047 | +123% | 0% | $9,800,562 |
| Venrock Adviser, LLC | 2% | 1,934,253 | +485% | 0.27% | $9,032,962 |
| SAMSARA BIOCAPITAL, LLC | 1.4% | 1,395,587 | -24% | 0.54% | $6,517,391 |
| STATE STREET CORP | 1.3% | 1,296,017 | +221% | 0% | $6,052,399 |
| Woodline Partners LP | 1% | 1,001,095 | 0% | 0.01% | $4,675,114 |
| GOLDMAN SACHS GROUP INC | 0.95% | 916,536 | +3.9% | 0% | $4,280,223 |
| NORTHERN TRUST CORP | 0.68% | 652,849 | +266% | 0% | $3,048,805 |
| VANGUARD FIDUCIARY TRUST CO | 0.59% | 572,038 | +19% | 0% | $2,671,417 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.56% | 542,128 | 0% | $2,531,738 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 95,923,522 | $447,942,684 | +$27,454,778 | $4.67 | 88 |
| 2026 Q1 | 90,401,419 | $373,355,951 | +$16,452,554 | $4.13 | 80 |
| 2025 Q4 | 85,919,846 | $343,681,474 | +$228,817,038 | $4.00 | 75 |
| 2025 Q3 | 13,652,105 | $46,690,414 | +$40,048,768 | $3.42 | 40 |
| 2025 Q2 | 2,150,633 | $4,086,190 | +$4,064,925 | $1.90 | 49 |
| 2025 Q1 | 83,045 | $20,007 | +$20,007 | $0.24 | 2 |